Dr. Sherman on Pazopanib in Anaplastic Thyroid Cancer

Video

In Partnership With:

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of anaplastic thyroid cancer with intensity-modulated radiation therapy (IMRT), paclitaxel, and pazopanib.

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of anaplastic thyroid cancer with intensity-modulated radiation therapy, paclitaxel, and pazopanib.

Anaplastic thyroid cancer is a large area of unmet need, Sherman says, as survival is typically less than six months. A phase II trial is examining the addition of pazopanib, a tyrosine kinase inhibitor, to radiation therapy and paclitaxel in patients with locally advanced anaplastic thyroid cancer or diseases that are metastatic elsewhere. Pazopanib has shown good response in differentiated thyroid cancer, but not in anaplastic thyroid cancer.

The idea behind this new combination is that adding pazopanib to a taxane will increase its benefit and that controlling the disease in the neck will lead to long term benefit. These drugs and radiation have not been used together before and toxicity must be controlled. Sherman says that although this is a phase II trial, overall survival is the primary outcome.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD